Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240435 · ClinicalTrials.gov registry record · Phase 3
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
NCT00240435: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00240435 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 491 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240435, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
Study Summary
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.
Interventions
- DEVICE 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- DEVICE 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2002-11 |
| Phase | Phase 3 |
What the finished NCT00240435 record still lists
NCT00240435 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler is the first listed.
NCT00240435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00240435 about?
NCT00240435 is a clinical study titled "12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD". The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the...
What is the current status of trial NCT00240435?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 2002-11.
What interventions are being tested in trial NCT00240435?
The interventions under investigation include: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler (DEVICE), 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler (DEVICE).
Who is sponsoring clinical trial NCT00240435?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00240435's enrollment target sits among peer trials
491 781st of 2000 higher than 1,219 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia